OESOPHAGUS

Effect of the GABA_B agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors

G H Koek², D Sifrim¹, T Lerut³, J Janssens¹, J Tack¹

¹ Center for Gastroenterological Research, University Hospital Gasthuisberg, Leuven, Belgium
² Center for Gastroenterological Research, University Hospital Gasthuisberg, Leuven, Belgium, and Department of Internal Medicine, Division of Gastroenterology and Hepatology, University Hospital Maastricht, the Netherlands
³ Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium

Correspondence to:
Correspondence to:
Dr J Tack, Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, 49, Herestraat, 3000 Leuven, Belgium;
Jan.tack{at}med.uzleuven.ac.be

Background and aims: A subset of patients with gastro-oesophageal reflux disease (GORD) with refractory symptoms during therapy with proton pump inhibitors (PPIs), have persistent non-acid duodeno-gastro-oesophageal reflux (duodenal reflux). The aim of the present study was to investigate the effect of the GABA_B receptor agonist baclofen, which was shown to inhibit the occurrence of transient lower oesophageal sphincter relaxations (TLOSRs) in patients with persistent non-acid duodenal reflux during PPI therapy.

Methods: Patients were eligible for the study if they had persistent reflux symptoms, normal pH monitoring, and pathological Bilitec monitoring during PPI treatment. Upper gastrointestinal endoscopy and reflux symptom score were performed at the beginning of the study. Baclofen 5 mg three times daily was associated with treatment, and was increased by 5 mg every fourth day until a maintenance dose of 20 mg three times daily was reached. A reflux symptom questionnaire, ambulatory pH monitoring, and Bilitec monitoring were repeated four days later while PPI and baclofen were continued. All data are given as mean (SEM) or median (interquartile range) and were compared using the Student’s t test or the Mann-Whitney U test.

Results: Sixteen patients (11 women, mean age 46 (3) years) with persistent heartburn or regurgitation for at least three months, in spite of PPI therapy, were included in the study. Erosive oesophagitis was present in seven patients (five with grade 1, two with grade 2). Under PPI therapy alone, all patients had normal acid exposure (0.3 (0.05; 2.2)% of the time) but pathological duodenal reflux exposure (13.8 (11.8; 15.5)% of the time). After addition of baclofen 20 mg three times daily, acid exposure was similar (0.4 (0.15; 2.3)% of the time; NS) but duodenal reflux had significantly decreased (6.1 (0.8; 10.3)% of the time; p<0.05). The number of duodenal reflux episodes and the number of longlasting duodenal reflux episodes (>5 minutes) was decreased, respectively, from 23 (14.5; 34) to 12 (5; 21) (p = 0.06) and from 5 (3; 8) to 2 (0.5;4.5) (p<0.05). The cumulative severity score for 14 reflux symptoms decreased from 10.3 (1.7) to 5.8 (1.3) (p<0.01). Four patients reported mild side effects of nausea or drowsiness.

Conclusions: The GABA_B receptor agonist baclofen improves duodenal reflux and associated reflux symptoms that persist during PPI therapy.

Keywords: gastro-oesophageal reflux disease; transient lower oesophageal sphincter relaxation; gamma-aminobutyric acid; proton pump inhibitors

Abbreviations: GORD, gastro-oesophageal reflux disease; TLOSR, transient lower oesophageal sphincter relaxation; GABA, gamma-aminobutyric acid; PPI, proton pump inhibitor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Lehmann, A., Antonsson, M., Holmberg, A. A., Blackshaw, L. A., Branden, L., Brauner-Osborne, H., Christiansen, B., Dent, J., Elebring, T., Jacobson, B.-M., Jensen, J., Mattsson, J. P., Nilsson, K., Oja, S. S., Page, A. J., Saransaari, P., von Unge, S. (2009). (R)-(3-Amino-2-fluoropropyl) Phosphinic Acid (AZD3355), a Novel GABAB Receptor Agonist, Inhibits Transient Lower Esophageal Sphincter Relaxation through a Peripheral Mode of Action. J. Pharmacol. Exp. Ther. 331: 504-512 [Abstract] [Full Text]  
• Keywood, C, Wakefield, M, Tack, J (2009). A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 58: 1192-1199 [Abstract] [Full Text]  
• Fass, R, Sifrim, D (2009). Management of heartburn not responding to proton pump inhibitors. Gut 58: 295-309 [Abstract] [Full Text]  
• Farre, R, van Malenstein, H, De Vos, R, Geboes, K, Depoortere, I, Vanden Berghe, P, Fornari, F, Blondeau, K, Mertens, V, Tack, J, Sifrim, D (2008). Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces. Gut 57: 1366-1374 [Abstract] [Full Text]  
• Galmiche, J P (2006). Impedance-pH monitoring in proton pump inhibitor resistant patients: ready for clinical application?. Gut 55: 1379-1381 [Full Text]  
• Bredenoord, A. J., Weusten, B. L. A. M., Timmer, R., Smout, A. J. P. M. (2005). Sleeve sensor versus high-resolution manometry for the detection of transient lower esophageal sphincter relaxations. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G1190-G1194 [Abstract] [Full Text]  
• Bettler, B., Kaupmann, K., Mosbacher, J., Gassmann, M. (2004). Molecular Structure and Physiological Functions of GABAB Receptors. Physiol. Rev. 84: 835-867 [Abstract] [Full Text]  
• (2003). Adding Baclofen to PPI Treatment for Refractory Reflux?. JWatch Gastroenterology 2003: 4-4 [Full Text]